Skip to main content
Livermore
Livermore
中文EN

Bleichroeder LP

SEC CIK
0001781002
Latest filing
Aug 13, 2026

The latest 13F from Bleichroeder LP covers Q2 2026 (filed Aug 13, 2026): 78 long positions worth $558.9M. The top 10 holdings make up 77.5% of the portfolio, and the largest is SPDR Gold Trust (GLD) at 31.3%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
9
Est. +$23.9M
Added
8
Est. +$11.1M
Reduced
7
Est. −$8.18M
Sold out
12
Est. −$9.45M

Top 5 holdings

Share of this quarter's portfolio value

  1. GLDSPDR Gold Trust
    31.3%$175.0MHistory
  2. GPGIGPGI, Inc.
    11.3%$63.0MHistory
  3. SPYSPDR S&P 500 ETF Trust
    9.0%$50.5MHistory
  4. RHLDResolute Holdings Management, Inc.
    8.1%$45.4MHistory
  5. LINLinde PLC
    5.6%$31.4MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. CUECue Biopharma, Inc.
    +$11.7MNewHistory
  2. COGTCogent Biosciences, Inc.
    +$3.87MNewHistory
  3. LIQTLiqtech International Inc
    +$3.14MAddedHistory
  4. DTILPrecision Biosciences Inc
    +$2.80MAddedHistory
  5. CGEMCullinan Therapeutics, Inc.
    +$2.73MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. CUECue Biopharma, Inc.
    +2.09 pp0.0% → 2.1%History
  2. DTILPrecision Biosciences Inc
    +1.26 pp1.6% → 2.8%History
  3. COGTCogent Biosciences, Inc.
    +0.69 pp0.0% → 0.7%History
  4. CGEMCullinan Therapeutics, Inc.
    +0.57 pp0.2% → 0.8%History
  5. SPIRSpire Global, Inc.
    +0.45 pp0.0% → 0.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. LINLinde PLC
    −$4.17MReducedHistory
  2. NMTCNeuroone Medical Technologies Corp
    −$3.11MSold outHistory
  3. JPMJPMorgan Chase & Co
    −$1.57MReducedHistory
  4. CUECue Biopharma, Inc.
    −$1.57MSold outHistory
  5. POCIPrecision Optics Corporation, Inc.
    −$1.19MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. IDNIntellicheck, Inc.
    −1.00 pp2.5% → 1.5%History
  2. NMTCNeuroone Medical Technologies Corp
    −0.54 pp0.5% → 0.0%History
  3. CUECue Biopharma, Inc.
    −0.27 pp0.3% → 0.0%History
  4. LINLinde PLC
    −0.26 pp5.9% → 5.6%History
  5. POCIPrecision Optics Corporation, Inc.
    −0.21 pp0.2% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$558.9M
−$19.6M (−3.4%) vs. prior quarter
Positions
78
−3 vs. prior quarter
Top 10 concentration
77.5%
Top 10 as share of value
Turnover
3.1%
Q2 2026, one quarter
Average holding period
14.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.17B (Q1 2021)

Q1 2021: $1.17BQ2 2021: $662.9MQ3 2021: $615.8MQ4 2021: $640.6MQ1 2022: $563.5MQ2 2022: $484.3MQ3 2022: $479.3MQ4 2022: $460.1MQ1 2023: $468.7MQ2 2023: $492.8MQ3 2023: $405.8MQ4 2023: $450.0MQ1 2024: $400.9MQ2 2024: $336.2MQ3 2024: $371.6MQ4 2024: $397.9MQ1 2025: $375.3MQ2 2025: $406.8MQ3 2025: $513.0MQ4 2025: $568.3MQ1 2026: $578.6MQ2 2026: $558.9M
Q1 2021Q2 2026
13F filings of Bleichroeder LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202678$558.9MGLDGPGISPYvs. Q1 2026SEC
Q1 2026May 14, 202681$578.6MGLDGPGIRHLDvs. Q4 2025SEC
Q4 2025Feb 13, 202673$568.3MGLDGPGIRHLDvs. Q3 2025SEC
Q3 2025Nov 14, 202572$513.0MGLDGPGILINvs. Q2 2025SEC
Q2 2025Aug 14, 202576$406.8MGLDGPGILINvs. Q1 2025SEC
Q1 2025May 15, 202578$375.3MGLDGPGILINvs. Q4 2024SEC
Q4 2024Feb 14, 202574$397.9MGLDGPGILINvs. Q3 2024SEC
Q3 2024Nov 13, 202473$371.6MGLDGPGILINvs. Q2 2024SEC
Q2 2024Aug 13, 202475$336.2MGLDLINGPGIvs. Q1 2024SEC
Q1 2024May 14, 202480$400.9MGLDLINBCvs. Q4 2023SEC
Q4 2023Feb 12, 202477$450.0MBCGLDLINvs. Q3 2023SEC
Q3 2023Nov 9, 202374$405.8MGLDBCLINvs. Q2 2023SEC
Q2 2023Aug 14, 202383$492.8MGLDBCLINvs. Q1 2023SEC
Q1 2023May 12, 202380$468.7MGLDBCLINvs. Q4 2022SEC
Q4 2022Feb 14, 202386$460.1MGLDBCLINvs. Q3 2022SEC
Q3 2022Nov 14, 202293$479.3MGLDBCLINvs. Q2 2022SEC
Q2 2022Aug 10, 202297$484.3MGLDBCLINvs. Q1 2022SEC
Q1 2022Jul 27, 2022Amended112$563.5MGLDLINBCvs. Q4 2021SEC
Q4 2021Feb 10, 2022104$640.6MGLDLININVEvs. Q3 2021SEC
Q3 2021Nov 15, 202197$615.8MGLDLINBCvs. Q2 2021SEC
Q2 2021Aug 16, 202192$662.9MGLDLINBCvs. Q1 2021SEC
Q1 2021Jun 3, 2021Amended81$1.17BGLDLINDurect Corp–SECSEC